Flomark: safer hospital infusions through pioneering devices and data analytics

Flomark：通过先进的设备和数据分析实现更安全的医院输液

• 批准号: 10027005
• 金额: $ 63.3万
• 依托单位: FLOMARK LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10027005
• 关键词: Flomark; safer; hospital; infusions; through

Maintaining correct fluid balance is particularly important for patient recovery. However, 20% of patients receiving intravenous (IV) fluids suffer medical complications because of incorrect IV administration.We will develop three innovations to address three pressing problems in fluid balance management.1) Hospital dripsIn 80% of all hospital admissions, a gravity administration set ("drip") is used to convey fluids directly into the patient's veins (infusion). But 85% of the time, the drip is used incorrectly, resulting in patients getting fluid too quickly or too slowly.We have patented an improved drip, the **Flomark Consumable**. It is intuitive to use, more reliable, saves staff time, and is the same cost as state-of-art drips. We will seek regulatory approval, test and manufacture this product. No flow meter capable of measuring this flow range is currently available.2) Infusion pumpsDuring many hospital infusions, an IV pump is used. Current pumps cannot sense how fast the fluid is flowing, and therefore must rely on expensive and heavy batteries and actuators to deliver fluid flow.We will combine the Flomark Consumable with electronics to easily sense and regulate flow, creating the **Flomark Regulator**. This will be a fraction of the cost of a pump, be easier to use, and have fewer drawbacks. We aim to produce a pre-production prototype.3) Fluid balanceIn intensive care (ICU), fluid balance (a patient's fluid input compared with fluid output) is very important. Although intensive care is highly resourced, this is monitored and calculated manually, and done inaccurately 35% of the time. Unlike cardiac and respiratory monitoring, there is no real-time data feed for fluid input and output, despite its acknowledged importance.We will modify the Flomark Consumable to measure fluid output (via a catheter), sensing this with the same Flomark Regulator design. This will allow accurate real time data to be produced for fluid _input and output_ for intensive care patients - a truly transformative step. Further to this, we will build software to analyse this data to predict potential patient harm (the **Flomark Software Platform**), and support informed clinical decisions and prescribing.These three innovations will vastly improve efficiency and safety in fluid management. They will disrupt the current industry, provide improved products for less cost, and improve data and thus care, saving healthcare providers worldwide a huge amount of money.**REFERENCES AVAILABLE ON REQUEST**

保持正确的液体平衡对患者的恢复尤为重要。然而，有20%接受静脉输液的患者会因为不正确的静脉输液而出现医疗并发症。我们将开发三项创新，以解决液体平衡管理中的三个紧迫问题。1）医院点滴在80%的住院患者中，重力输液装置（“点滴”）用于将液体直接输送到患者的静脉（输液）。但85%的情况下，滴注器使用不当，导致患者输液过快或过慢。我们已经为改进的滴注器申请了专利，即 **Flomark耗材 **。它使用直观，更可靠，节省工作人员的时间，并且与最先进的滴水器成本相同。我们将寻求监管部门的批准，测试和生产这种产品。目前没有能够测量该流量范围的流量计。2）输液泵在许多医院输液期间，使用IV泵。目前的泵无法感知流体流动的速度，因此必须依靠昂贵而沉重的电池和执行器来输送流体流量。我们将联合收割机与电子设备相结合，以轻松地感知和调节流量，创造出 **Flomark调节器 **。这将是一个泵的成本的一小部分，更容易使用，并具有较少的缺点。我们的目标是生产一个预生产原型。3）液体平衡在重症监护（ICU）中，液体平衡（患者的液体输入与液体输出相比）非常重要。虽然重症监护是高度资源化的，但这是手动监测和计算的，并且有35%的时间是不准确的。与心脏和呼吸监测不同的是，尽管液体输入和输出的重要性已得到公认，但它没有实时数据输入。我们将修改Flomark耗材以测量液体输出（通过导管），并使用相同的Flomark调节器设计进行传感。这将允许为重症监护患者的流体输入和输出产生准确的真实的时间数据-这是一个真正的变革性步骤。除此之外，我们还将构建软件来分析这些数据，以预测潜在的患者伤害（**Flomark软件平台 **），并支持明智的临床决策和处方。这三项创新将大大提高液体管理的效率和安全性。它们将颠覆当前的行业，以更低的成本提供更好的产品，改善数据，从而改善护理，为全球医疗保健提供商节省大量资金。可应要求提供参考资料 **